Delhi High Court hears Glenmark Pharma's petition against NPPA's pricing order for anti-diabetic drugs, claiming arbitrary pricing and seeking exemption due to DCGI approval.
The Drug Controller General of India (DCGI) plans to hold walk-in meetings with stakeholders to improve the ease of doing business in India. Starting on February 20, these meetings will take place every Tuesday and Thursday at the CDSCO Headquarters. The DCGI, responsible for drug approval, clinical trials, drug standards, imported drug quality control, and State Drug Control Organization coordination, aims to hear complaints, grievances, and suggestions for swift resolution.
The document states the draft regulatory guidelines for sampling of drugs, cosmetics and medical devices by drugs inspectors of central and state drug authorities. "This guideline will be useful for effective surveillance for quality and efficacy of drugs and cosmetics by adopting uniform drug sampling methodology for drug inspectors under drug regulatory authorities of state and central," it said.
DGGI has busted 1,700 fake Input Tax Credit (ITC) cases worth Rs 18,000 crore and arrested 98 people. Using data analysis and advanced tools, DGGI apprehended tax evaders involved in creating fake firms and companies. In one case, a firm in Haryana generated E-way bills and created Rs. 1,100 crore fraudulent ITC.
Products made for the Indian market cannot be exported, the central health regulator has said in an alert issued to all of its port offices across India, asking them to watch the exports by merchant exporters, News18 has learnt.
The DCGI has asked all port offices to ensure that products meant for the "India market only" are not exported after receiving complaints about the unauthorised export of drugs meant for the local market.
The pharmaceutical industry, and the central drug regulatory agency, faced a severe reputation crisis following the deaths of 70 children in Gambia due to contaminated cough syrups in 2022. A few months later, Rajeev Raghuvanshi took over as the Drug Controller General of India and is currently driving a transformational change. Can he set a high bar for product quality?
The Drugs Controller General of India (DCGI) has issued guidelines directing hospitals and blood banks to charge only processing fees for blood to prevent overcharging. The decision, based on the perspective that "blood is not for sale," was conveyed to states and Union Territory drugs controllers.